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Background: Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product
halichondrin B. Eribulin is a tubulin-binding drug and approved in many countries worldwide for treatment of
certain patients with advanced breast cancer. Here we investigated antiproliferative and antiangiogenic effects of
eribulin on vascular cells, human umbilical vein endothelial cells (HUVECs) and human brain vascular pericytes
(HBVPs), in vitro in comparison with another tubulin-binding drug, paclitaxel.
Methods: HUVECs and HBVPs were treated with either eribulin or paclitaxel and their antiproliferative effects were
evaluated. Global gene expression profiling changes caused by drug treatments were studied using Affymetrix
microarray platform and custom TaqMan Low Density Cards. To examine effects of the drugs on pericyte-driven
in vitro angiogenesis, we compared lengths of capillary networks in co-cultures of HUVECs with HBVPs.
Results: Both eribulin and paclitaxel showed potent activities in in vitro proliferation of HUVECs and HBVPs, with
the half-maximal inhibitory concentrations (IC50) in low- to sub-nmol/L concentrations. When gene expression
changes were assessed in HUVECs, the majority of affected genes overlapped for both treatments (59%), while in
HBVPs, altered gene signatures were drug-dependent and the overlap was limited to just 12%. In HBVPs, eribulin
selectively affected 11 pathways (p < 0.01) such as Cell Cycle Control of Chromosomal Replication. In contrast,
paclitaxel was tended to regulate 27 pathways such as PI3K/AKT. Only 5 pathways were commonly affected by
both treatments. In in vitro pericyte-driven angiogenesis model, paclitaxel showed limited activity while eribulin
shortened the formed capillary networks of HUVECs driven by HBVPs at low nmol/L concentrations starting at day
3 after treatments.
Conclusions: Our findings suggest that pericytes, but not endothelial cells, responded differently, to two
mechanistically-distinct tubulin-binding drugs, eribulin and paclitaxel. While eribulin and paclitaxel induced similar
changes in gene expression in endothelial cells, in pericytes their altered gene expression was unique and
drug-specific. In the functional endothelial-pericyte co-culture assay, eribulin, but not paclitaxel showed strong
efficacy not only as a cytotoxic drug but also as a potent antivascular agent that affected pericyte-driven in vitro
angiogenesis.
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Formation and maintenance of new vascular vessels sup-
porting tumor growth is a process which involves complex
communications among different cell types. Interactions
between endothelial cells and supporting pericytes and
vascular smooth muscle cells lead to active remodeling
during angiogenesis [1,2]. It is now well established that
pericytes participate in angiogenic signal transduction and
direct control of endothelial cell proliferation and thus
play an important role in vascular morphogenesis and
function [3]. Paracrine pericyte-endothelial interactions
through VEGF, PDGF, and angiopoitin signaling promote
tumor angiogenesis, pericyte recruitment and pericyte
coverage of tumor vessels [4-7]. It is also known that peri-
cytes shield endothelial cells from apoptotic signals [8]. As
such, pericytes, in conjunction with endothelial cells,
present a logical target for antiangiogenic therapeutic
strategies.
Several approaches are currently employed to target
tumor angiogenesis. Inhibition of VEGF signaling by spe-
cific antibodies or small molecule agents directed against
VEGFR2 tyrosine kinase has been shown to inhibit forma-
tion and outgrowth of new blood vessels and several
angiogenesis inhibitors have been used as anticancer ther-
apy in patients [9]. In addition to inhibition of angiogen-
esis, recent studies showed that pharmacological VEGF
inhibition, especially with anti-VEGF antibody, normalizes
vessel structure and function through pericyte recruitment
to disorganized tumor vessels [10,11]. Since normalization
of tumor vasculature improves their perfusion and oxy-
genation, cytotoxic drugs were given in combination with
anti-VEGF antibody causing the best response to radiation
or cytotoxic therapy [12]. On the other hand, roles of peri-
cytes in resistance to antiangiogenesis therapy have
emerged, since most of cancer patients acquire resistance
and become refractory to anti-VEGF therapy [13].
Another approach which is used to selectively target ab-
normal tumor vasculature is to apply agents which show
vascular-disrupting activity to already formed blood vessels.
Tumor vascular disrupting agents (VDA) cause selective in-
duction of apoptosis in endothelial cells and induce vascu-
lar damage in already formed tumors [14]. Several specific
VDAs are now undergoing clinical evaluation [15], al-
though no VDA has been approved for cancer therapy.
Tubulin-binding agents were known to show antivas-
cular effects represent both antiangiogenesis and vascu-
lar disrupting activity, which were well reported for
paclitaxel and combrestatin analogs, respectively [16,17].
It is apparent that microtubules play an important role
in angiogenesis and maintenance and stability of tumor
vessels. Eribulin mesylate (eribulin), a non-taxane inhibi-
tor of microtubule dynamics, belongs to the halichon-
drin class of antineoplastic drugs [18]. Eribulin’s novel
mode of inhibiting microtubule dynamics differs frommost other tubulin-targeting agents, and involves inhib-
ition of the microtubule growth phase without affecting
the shortening phase, together with sequestration of tubu-
lin into non-productive aggregates [19]. This results in
blockage of normal mitotic spindle formation, irreversible
mitotic block and cell death by apoptosis [18,20,21]. At
the biochemical level, eribulin achieves these results by
specifically binding with high affinity to a small number of
sites on the plus ends of microtubules [22].
In this paper we examined effects of eribulin on
HUVECs and HBVPs in vitro. We analyzed effects of eri-
bulin on global gene expression in HUVECs and HBVPs
in a comparison with paclitaxel, which is a stabilizer of
microtubule dynamics and has a distinct mechanism from
eribulin. We determined effects of these two drugs on cell
proliferation in mono-cultures of HUVECs and HBVPs,
and employed a newly developed capillary network forma-
tion assay, in which HBVPs co-cultured with HUVECs to
promote network formation, in order to assess antivascu-
lar activities of both drugs in the context of physiologically
relevant cell-cell interactions.
Materials and methods
Cell cultures and compounds
Primary human umbilical vein endothelial cells (HUVECs)
were either purchased from Lonza (Walkersville, MD) or
isolated from a single umbilical cord by a method de-
scribed previously [23] and maintained in endothelial cell
growth medium EGM-2 supplemented with EGM-2
SingleQuots except for hydrocortisone (Lonza,). Human
brain vascular pericytes (HBVPs) were obtained from
ScienCell Research Laboratories (Carlsbad, CA), and were
grown in Pericyte Medium (ScienCell). To confirm their
authenticity, cultured HBVPs were examined for expres-
sion levels of 6 key pericyte markers grown on plastic
(Additional file 1). Both HUVECs and HBVPs were grown
on collagen type I-coated plastic ware. For cell prolifera-
tion and gene expression experiments, cells were used at
<5 passages.
Green fluorescent protein (AcGFP)-expressing HUVECs
were established by infection with a retrovirus for gene
transfer of AcGFP followed by collecting high level
AcGFP-expressing HUVECs by fluorescence activated cell
sorting. Cells were maintained at 37°C in a humidified at-
mosphere containing 5% CO2.
Paclitaxel was purchased from Sigma-Aldrich (Saint
Louis, MO) and Wako Pure Chemical (Osaka, Japan). Eri-
bulin mesylate was manufactured by Eisai Co., Ltd (Ibaraki,
Japan). Both compounds were dissolved in DMSO to yield
a stock concentration of 1 mmol/L.
Cell proliferation assay
HUVECs and HBVPs were plated at 3000 cells per well
in 96-well plates. Three hours later serial dilutions of
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treated with 0.1% DMSO. Cell growth was assessed
4 days later using the CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, WI). Three experi-
ments were performed, each in triplicate. The mean of
the half maximal inhibitory concentration (IC50) value
and 95% confidence interval (CI) were calculated based
on IC50 values generated from separate sigmoidal curves
representing the growth inhibition activity versus the
eribulin and paclitaxel concentration of three independ-
ent experiments. Statistical analyses were performed
using the GraphPad Prism version 5.02 (GraphPad Soft-
ware, San Diego, CA).
HUVEC/HBVP co-culture assay and measurement of
pericyte-covered capillary network length reduction
HBVPs and AcGFP-expressing HUVECs were diluted
and mixed to densities of 1.87 × 105 cells/mL and 1.3 ×
104 cells/mL with medium, respectively. Cell suspensions
were dispensed at 100 μL per well in black-walled, clear-
bottomed, collagen type I-treated 96-well plates (Greiner
Bio One, Frickenhausen, Germany) and incubated for
10 days with culture medium changes every 2 days.
To measure effects of compounds on capillary network
lengths in HUVEC/HBVP co-cultures, 100 μL solutions
of eribulin, paclitaxel or 0.1% DMSO (vehicle control)
were exchanged into each well and incubated for 5 days.
Three independent experiments were performed in trip-
licate. Fluorescence microscopy was performed every
day for 5 days using an IN Cell Analyzer 1000 (GE
Healthcare, Piscataway, NJ) to obtain images of pericyte-
covered capillary networks formed by AcGFP-expressing
HUVECs under co-culture conditions. Images were
negative/positive inverted and high-contrasted by Irfan
View software version 3.61 (Irfan Skiljan, Wierner Neus-
tadt, Austria), followed by analysis using Angiogenesis
Image Analyzer software version 2.0 (Kurabo, Osaka,
Japan) to measure lengths of pericyte-covered capillary
networks. Data for pericyte-covered capillary network
lengths were expressed as means + SEM.
IC50’s of 5-day treatments in three independent experi-
ments were analyzed by nonlinear regression analysis,
and means of three IC50 values were determined. Statis-
tical analyses were performed using GraphPad Prism
version 5.04 (GraphPad Software).
Measurement of cell viability in co-culture
Assessment of cell viability in the co-culture assay was
performed by modification of the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide colorimetric assay
[24]. After measurement of pericyte-covered capillary
network lengths in the HUVEC/HBVP co-culture assay,
medium in wells was exchanged with 100 μL of 11-fold
media-diluted WST-8 reagent (Cell Counting Kit-8,Dojindo Laboratories, Kumamoto, Japan), followed by
incubation for one additional hour. The optical density
(OD) at 450 nm of each well was measured with a mi-
croplate reader (SpectraMax 250, Molecular Devices,
Sunnyvale, CA), with a reference wavelength of 650 nm.
Data for cell viability were expressed as means + SEM.
Microarray analysis
HUVECs and HBVPs were plated at 1 × 105 cells per
well in 12-well plates. The next day, cells were treated
with compounds at 10 × IC50 concentrations as deter-
mined in cell proliferation assays. Control wells were
treated with 0.1% DMSO in culture media. Experiments
were done in triplicates. Twenty four hours later, cells
were collected and RNA was extracted using an RNeasy
Mini kit (Qiagen, Valencia, CA) with DNase I on-
column treatment according to the manufacturer’s
protocol. RNA was quantified using Nanodrop ND-1000
(Thermo Scientific, Wilmington, DE). For each sample,
1 μg total RNA was used to prepare biotinylated frag-
mented cDNA for analysis on Human Exon 1.0 ST ar-
rays (Affymetrix, Santa Clara, CA). Sample preparation
was performed in accordance with manufacturer’s in-
structions using the WT Expression kit (Life Technolo-
gies, Carlsbad, CA) and the GeneChip WT (Whole
Transcript) Terminal Labeling Kit (Affymetrix). Hybrid-
izations were conducted according to the GeneChip Ex-
pression Analysis Technical Manual (Affymetrix). Arrays
were washed and stained using Affymetrix Fluidics Sta-
tion 450, and finally scanned using Affymetrix GeneChip
Scanner 3000.
Gene chips were analyzed using Affymetrix Microarray
Analysis Suite (MAS) version 5.0 to obtain raw data.
Fluorescence intensities of scanned images were quanti-
fied, corrected for background noise, and RMA normal-
ized using Refiner software (Genedata, Basel, Switzerland).
Normalization procedure within RMA consisted of a GC
background subtraction, quantile normalization and
summarization. QC analysis of the microarrays was
performed according to the standard protocol within
Genedata software. All microarrays passed QC criteria.
Statistical analysis was performed with Expressionist soft-
ware (Genedata). We restricted our analysis to gene inten-
sities >100, based on the detection limit of the Affymetrix
gene chip. Gene expression levels of untreated samples
were compared to those from treated samples using t-test
analysis. Comparisons were limited to p-values of 0.05 in
order to eliminate 95% of false positives from the data set,
and to fold change levels of at least 1.5 in order to remove
background effects.
Quantitative real time PCR analysis
Reverse transcription was carried out with 2.5 μg of total
RNA using a Superscript VILO kit (Life Technologies).
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tive polymerase chain reaction (qPCR) using custom
TaqMan Low Density Array (TLDA) (Life Technologies)
with ABI 7900HT (Life Technologies). Selected gene
probes related to differentially expressed genes identified
in the microarray experiment were used for TLDA
(Additional file 2). Data were normalized using Expres-
sionist (Genedata).
Hierarchical clustering was done using Genedata soft-
ware. Genes differentially expressed between eribulin
and control and between paclitaxel and control were
uploaded into Ingenuity Pathway Analysis (IPA; Ingenu-
ity Systems, Redwood City, CA), and only significantly
affected signaling pathways were reported with the cut
off value of p < 0.01 for pathway enrichment.
Results
Effects of eribulin and paclitaxel on cell proliferation
in vitro
Tubulin-binding drugs exert their effects on actively div-
iding cells by disrupting normal mitotic spindle forma-
tion and thus causing cell cycle blockage in mitosis
leading ultimately to cell death. It was previously shown
that eribulin is a highly active compound in growth in-
hibition of numerous cancer cells [18]. To evaluate drug
effects on proliferation of HUVECs and HBVPs, we
tested eribulin and paclitaxel in a standard cell prolifera-
tion assay. Table 1 shows the results of this analysis.
Compared to HBVPs, both compounds were more active
against HUVECs, showing similar IC50 values in the
sub-nmol/L range: 0.54 for eribulin and 0.41 for pacli-
taxel. HBVPs were more resistant to both eribulin and
paclitaxel, with IC50 values of 1.19 and 2.19 nmol/L,
respectively.
Gene expression analysis of eribulin- and paclitaxel-
treated HUVECs and HBVPs
To evaluate transcriptional changes in HUVECs and
HBVPs caused by treatment with eribulin and paclitaxel,
we used whole human genome microarrays. We selected
comparable functional concentrations of both com-
pounds based on their activities in cell growth inhibition
assays (10 × IC50) for 24 hours treatment based on the
number of genes altered after comparing several differ-
ent conditions such as concentration and duration of
treatments.Table 1 Inhibition of HUVEC and HBVP cell growth by
eribulin and paclitaxel
Growth inhibition, IC50 (nmol/L)
Cell type Eribulin Paclitaxel
HUVEC 0.54 ± 0.09 0.41 ± 0.12
HBVP 1.19 ± 0.20 2.19 ± 0.55In HUVECs, eribulin significantly altered expression
of 321 genes compare to control vehicle-treated cells
(Figure 1A). Paclitaxel caused transcriptional changes of
356 genes compare to control. When we compared these
two signatures, more than 59% of genes overlapped be-
tween the two groups (Venn diagram, Figure 1B). It
should be noted that all 251 overlapping genes changed
expression in the same direction in eribulin and pacli-
taxel treated cells: 235 genes were down-regulated while
16 were up-regulated after both treatments. Interest-
ingly, direct comparison of eribulin versus paclitaxel
treatments showed significantly different expression
changes in only 29 genes. Both treatments led to down-
regulation, not up-regulation, of a majority of the af-
fected genes in HUVECs (Additional file 3).
A different pattern of expression changes was observed
in HBVPs with both drug treatments. Eribulin altered ex-
pression levels of 172 genes while paclitaxel changed ex-
pression of 416 genes compared to vehicle-treated cells
(Figure 1C). Only 63 genes (12%) of the total number
of 525 altered genes overlapped between the two drugs
(Figure 1D). Eribulin caused down-regulation of 105 genes
and up-regulation of 67 genes, while paclitaxel led to
higher number of up-regulated genes (348) compared to
down-regulated genes (68) (Additional file 3). Direct com-
parison of eribulin- and paclitaxel-treated changes of gene
expression profiling showed a significant number of genes
(594) differentially altered in HBVPs. These data indicate
that, in contrast to HUVECs, transcriptional changes in
HBVP were very drug-specific.
Comparison of gene profiles in HUVECs and HBVPs re-
vealed only 14 altered genes that were common to all treat-
ments. Four of these, BTG2, CDC45, CSE1 and MCM5,
were cell cycle related genes. The largest group of 6 genes
among the 14 common genes consisted of 5 linker his-
tone H1 gene family members (HIST1H1A, HIST1H1B,
HIST1H1D, HIST1H2AB/HIST1H2AE and HIST1H2BM)
and one nucleosome histone H2 gene (HIST2H2AC). In
addition, anti-silencing function 1B histone chaperone
(ASF1B) was also among commonly effected genes.
To evaluate differential effects of eribulin and pacli-
taxel on pericytes in more details, we performed path-
way analysis using Ingenuity software (Ingenuity
Pathway Analysis) (Table 2). Results showed that eribu-
lin significantly affected pathways related to cell cycle
control of chromosomal replication, RAN signaling, as
well as polyamine regulation and mismatch repair. On
the other hand, paclitaxel regulated PI3K/AKT, HGF
and WNT pathways as well as stress response and p53
signaling pathways and others. These results indicate
that pericyte functions in general might be affected dif-
ferently by eribulin and paclitaxel.
We confirmed a subset of genes differentially expressed
in HBVPs after treatment with eribulin versus paclitaxel
Treatment
Number of significantly 
altered genes




Number of significantly 
altered genes
vs Control vs Eribulin 
Eribulin 172 -
Paclitaxel 416 594
70            251            105
59%
PaclitaxelEribulin







Figure 1 Gene expression analysis of vascular cells treated with eribulin and paclitaxel. A. Number of differentially expressed genes in
HUVECs treated with eribulin or paclitaxel. B. Comparison of eribulin and paclitaxel gene signatures in HUVECs by Venn diagram. C. Number of
differentially expressed genes in HBVPs. D. Comparison of eribulin and paclitaxel gene signatures in HBVPs by Venn diagram. Analysis was
restricted to genes with signal intensities >100, p-values < 0.05 and fold change levels of at least 1.5 in order to remove background effects.
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We showed that expression of 37 genes was significantly
changed in both of eribulin and paclitaxel treatments as
measured by qPCR. Furthermore, expression alterations of
several genes were confirmed by Western blot analysis
(Additional file 4). These altered genes formed drug-
specific signatures and were clustered according to the
treatment. Three major clusters of genes were identified,
one with downregulated genes for both eribulin and pacli-
taxel (5 genes) and another one with upregulated genes
for both treatments (10 genes), but altered levels with eri-
bulin treatment were more robust. The third group with
downregulated genes for eribulin and upregulated genes
for paclitaxel signature contained largest numbers of genes
(22 genes) clustered into two groups, one with ANGPT2,
CXCL12, CXCL1, SLC2A12, TXNIP, FAM198B, PTGS2,
RHOU, TNFAIP3 genes and another with ADMTS1,
EPHA7, IGFBP3, ALDH1A3, RANBP3L, EMCN, GPAM,
FGD6, WNT2B, TUBA1A, CCL2, TUBB, TUBB2A genes.
Effects of eribulin and paclitaxel on capillary networks in
endothelial cell-pericyte co-cultures
We examined effects of eribulin and paclitaxel on
pericyte-covered capillary networks in a unique assay
system in which HUVECs and HBVPs were co-cultured.
In this assay system, AcGFP-expressing HUVECs form
pericyte-covered capillary networks driven by HBVPs,
since HUVECs mono-culture in the 2D condition never
formed networks without pericytes or fibroblasts (data
not shown), and the length of these networks can be
measured and analyzed after drug treatment. Figure 3
shows pericyte-covered capillary network length alter-
ations by the treatment with eribulin or paclitaxel. In
both groups, pericyte-covered capillary network lengthswere decreased in a time-dependent manner and max-
imum at 5 days after treatment. IC50 values at 3- and 5-
day treatments with eribulin were 3.6 nmol/L and
1.5 nmol/L, respectively, while with paclitaxel, IC50 values
were >1 μmol/L at 3 days and 13 nmol/L at 5 days
(Table 3). To evaluate effects of compounds on capillary
networks formed with only HUVECs, we used standard
sandwich tube formation assay (Additional file 5). Capil-
lary network formation was induced by VEGF stimulation
with HUVECs cultured between two layers of collagen gel
without co-culturing with HBVPs. In this assay, eribulin
and paclitaxel showed similar IC50 values (0.65 - 0.72 for
eribulin and 1.18 - 1.26 for paclitaxel) in shortening capil-
lary network at 4 days after treatment, which suggest that
pericyte-covered condition is an important component of
differential response of capillary network to the treatment
with eribulin in co-culture assay compared to paclitaxel.
Cell viability in the co-culture assay after 5 days of treat-
ment with eribulin was slightly decreased (about 20%)
(Figure 4). Since majority cells in co-culture were HBVPs,
we assume that most of the signal in this assay came from
pericyte cells. However, it might reflect shorter length of
HUVECs network, because there was slightly higher cell
viability in the co-culture assay compared to HBVPs mono-
culture (Additional file 6). These data indicate that eribulin
has greater antivascular effects on pericyte-covered capillary
network shortening relative to its antiproliferative effects
on HUVECs, whereas effects of paclitaxel on pericyte-
covered capillary network shortening was much weaker
than its antiproliferative effects on HUVECs.
Discussion
In addition to normal development, angiogenesis plays an
important role in tumor growth [25]. However, tumor
Table 2 Signaling pathways affected by eribulin and paclitaxel in HBVPs
Eribulin affected pathways p values (-log) Paclitaxel affected pathways p values (-log)
Cell cycle control of chromosomal replication 6.85E+00 PI3K/AKT signaling 5.91E+00
Granzyme A signaling* 6.27E+00
Hepatic fibrosis/hepatic stellate cell
activation*
4.59E+00
RAN signaling 3.37E+00 NRF2-mediated oxidative stress response 4.11E+00
Polyamine regulation in colon cancer 3.03E+00 Glucocorticoid receptor signaling 4.07E+00
Role of macrophages, fibroblasts and endothelial cells in
rheumatoid arthritis*
2.79E+00 Aryl hydrocarbon receptor signaling 3.89E+00
Airway pathology in chronic obstructive pulmonary disease 2.68E+00 IGF-1 signaling 3.82E+00
IL-17A signaling in fibroblasts* 2.44E+00 p53 signaling 3.79E+00
Hepatic fibrosis/hepatic stellate cell activation* 2.10E+00 Granzyme A signaling* 3.30E+00
Bladder cancer signaling* 2.09E+00 Cell cycle regulation by BTG family proteins 3.19E+00
Mismatch repair in eukaryotes 2.06E+00 Aldosterone signaling in epithelial cells 2.95E+00
Putrescine degradation III 2.01E+00 MIF regulation of innate immunity 2.87E+00
CDK5 signaling 2.70E+00
Wnt/b-catenin signaling 2.60E+00
Role of macrophages, fibroblasts and
endothelial cells in Rrheumatoid arthritis*
2.42E+00
HGF signaling 2.38E+00
MIF-mediated glucocorticoid regulation 2.38E+00
Estrogen receptor signaling 2.37E+00
Role of IL-17A in arthritis 2.34E+00
VDR/RXR activation 2.31E+00
Role of CHK proteins in cell cycle checkpoint
control
2.30E+00
IL-17A signaling in fibroblasts* 2.28E+00
Stearate biosynthesis I (animals) 2.28E+00
Superoxide radicals degradation 2.24E+00
Apoptosis signaling 2.06E+00
CD40 signaling 2.06E+00
Bladder cancer signaling* 2.03E+00
Melanoma signaling 2.00E+00
Genes with significantly changed expression levels compare to controls were analyzed using Ingenuity Pathway Analysis. Cell signaling pathways significantly
affected by eribulin or paclitaxel treatments are shown.
*Common pathways for both treatments.
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number of properties. Tumor vasculature is known to be
grossly disorganized and tortuous. Furthermore, tumor
vasculature is leakier than normal vasculature because it
grows fast and does not have close interactions with peri-
cytes. Interactions between endothelial cells and pericytes
in the blood vessel wall are important processes in the
regulation of vascular formation, stabilization, remodeling
and function. Failure of such interactions are implicated in
human pathological conditions, including diabetic micro-
angiopathy [26], ectopic tissue calcification [27], stroke
[28] and cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)syndrome, one of the most common inherited small vessel
diseases of the brain [29]. Tumor vasculature is heteroge-
neous in its interaction with pericytes, and many reports
indicate that those having a “mature” appearance, defined
primarily as having close endothelial cell-pericyte interac-
tions, show resistance to antiangiogenic therapies [30].
To shed light on effects of eribulin on tumor angio-
genesis, we studied HUVECs and HBVPs as models of
endothelial cells and pericytes in tumor vasculature. We
showed that these two cell types responded differently to
eribulin and paclitaxel treatment by specific changes in
expression of multiple genes. In HUVECs, both eribulin
and paclitaxel led to down-regulation of most affected
min max
Figure 2 Hierarchical clustering of differentially expressed genes in HBVPs. HBVPs were treated with eribulin or paclitaxel (PTX) for 24 hours
in triplicates. Expression levels of selected genes identified as differentially expressed in microarray experiment were analyzed by qPCR using
custom TLDAs. Genes were clustered according to their expression patterns.
Agoulnik et al. Vascular Cell 2014, 6:3 Page 7 of 11
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eribulin and paclitaxel signatures in HBVPs were clearly
different from those in HUVECs.
We found that among 14 genes common for both drugs
and both cell types, 4 genes were related to cell cycle pro-
gression (BTG2, CDC45, CSE1 and MCM5). The largest
group of 6 common genes, all of which were down-
regulated, was made up of histones, with 5 of these belong-
ing to the H1 gene family. In addition, 1B histone chaperone
gene ASF1B was also down-regulated by both drugs in
HUVECs and HBVPs. There are 11 known H1 family mem-
bers in the human genome, and 5 of those were found inthis study to be down-regulated by the two tubulin-binding
drugs under study. The H1 histones work as linkers for nu-
cleosomal core particles and have an important role in es-
tablishing and maintaining chromatin structure and
regulation of gene activity [31]. Down-regulation of H1 his-
tones causes de-condensation of chromatin and possibly up-
regulation of gene transcription.
Our data showed that in HBVPs, gene expression
changes caused by eribulin and paclitaxel were dramatic-
ally different. Only 12 percent of genes were similarly af-
fected by both drugs, while the rest showing drug-specific
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Figure 3 Pericyte-covered capillary network length alterations by eribulin and paclitaxel in HUVEC and HBVP co-culture assay. A.
HUVECs and HBVPs in co-culture were treated with eribulin or paclitaxel for 5 days and pericyte-covered capillary network lengths were calculated
by the length of networks formed by HUVECs. Data represent means + SEM from three independent experiments. B. Representative images of
pericyte-covered capillary network captured on 5-day treatment. AcGFP-expressing HUVECs form networks (in black) which are responding to the
drug treatments by shortening of their lengths.
Agoulnik et al. Vascular Cell 2014, 6:3 Page 8 of 11
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down-regulated and by eribulin. Direct comparison of eri-
bulin’s versus paclitaxel’s gene expression profiles showed
a large number of differentially expressed genes. These
data indicate that either the direction of altered expression
was opposite for the two drugs, or the degrees of alter-
ation were significantly different between eribulin and pac-
litaxel treatment.Table 3 Effects of eribulin and paclitaxel on capillary
networks in HUVEC and HBVP co-cultures
Treatment Network shortening, IC50 (nmol/L)
Day 1 Day 2 Day 3 Day 4 Day 5
Eribulin >1,000 >1,000 3.6 2.1 1.5
Paclitaxel >1,000 >1,000 >1,000 >1,000 13A number of observed differentially expressed eribulin-
specific genes (Additional file 3, highlighted in red) were
previously reported to be associated with angiogenesis,
pericyte biology and vascular remodeling (NOTCH3,
PTX3,TNFAIP1, PGF, GREM1, TIMP4, LIPG, MYOCD)
[32-36]. Of particular interest is NOTCH3, a gene encod-
ing one of the notch family members and known to be
underlying cause of CADASIL [37,38]. NOTCH signaling
is critical for maintenance of normal vascular structure,
angiogenesis and vascular remodeling in both physio-
logical and pathological conditions [39,40]. In our study
we detected significant upregulation of NOTCH3 expres-
sion after eribulin treatment in HBVPs.
To evaluate specific effects of eribulin on signaling
pathways, we performed pathway analysis using Ingenu-
ity software. This analysis showed that in pericytes,
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Figure 4 Cell viabilities after treatment with eribulin or paclitaxel in HUVEC and HBVP co-cultures. Cell viabilities were measured by the WST-8
assay in HUVEC/HBVP co-cultures treated with eribulin or paclitaxel for 5 days. Data represent means + SEM from three independent experiments.
Agoulnik et al. Vascular Cell 2014, 6:3 Page 9 of 11
http://www.vascularcell.com/content/6/1/3eribulin compared to paclitaxel. In particular, cell cycle
control of chromosomal replication including RAN sig-
naling and mismatch repair pathways were among most
significantly changed.
Most studies published to date have used in vitro
endothelial cell-based vascular disruption assays to
evaluate activities of compounds against newly formed
capillary-like structures. In such assays, endothelial cells
that are plated on thick layers of Matrigel form networks
of cord-like structures, reminiscent of newly formed ves-
sels. Treatment with antivascular compounds results in
disruption of the integrity of such cord-like networks.
However, such assays, using only endothelial cells, do
not take into account the physiologically-relevant close
interactions between endothelial cells and supporting
pericytes within the context of tumor vasculature. To
overcome this limitation, we developed a novel assay in
which AcGFP-transfected endothelial cells grow and
form capillary networks in co-culture with pericytes.
The effects of two tubulin-targeting compounds, eribulin
and paclitaxel, on network formation were evaluated in
this assay by measuring the lengths of pericyte-covered
capillary networks. We found that eribulin and paclitaxel
behaved dramatically different in this assay. Eribulin, in
contrast to paclitaxel, showed significant antivascular ac-
tivity causing dramatic pericyte-covered capillary net-
work shortening effects relative to its antiproliferative
effects on HUVECs. On the other hand, pericytes
seemed to protect endothelial networks under paclitaxel
treatment conditions and thus network shortening activ-
ity was much weaker compared to its antiproliferative ef-
fects on HUVECs. Thus, eribulin appeared to impair
interaction of pericytes with endothelial cells through
the activity against pericytes differently from paclitaxel
in this assay. Consequently, eribulin showed much
higher activity as an anti-vascular agent than to pacli-
taxel in this co-culture assay. Interestingly, in the sand-
wich tube formation assay in which HUVECs can formcapillary network without co-culturing with HBVPs, eri-
bulin and paclitaxel showed similar IC50 values in short-
ening capillary network at 4 days after treatment. This
strongly supports the above hypothesis. In future studies,
it will be important to compare and further define this
newly discovered antipericyte-based antivascular prop-
erty of eribulin with other known tubulin-binding drugs
both in in vitro and in vivo angiogenesis models.Conclusions
Current study showed that eribulin, but not paclitaxel,
causes dramatic shortening and interruption of pericyte-
driven capillary networks formed by HUVECs in co-culture
with HBVPs. The effect was observed at compound’s con-
centrations which did not induce significant toxicity in peri-
cytes of confluent state. Gene expression profiling of
pericytes treated with eribulin showed specific signature
different from paclitaxel’s one. We propose that observed
eribulin’s antiangiogenic effect in co-culture model is based
on drug’s effects against pericytes.Additional files
Additional file 1: Expression of key pericyte markers in HBVPs and
HUVECs. Expression of α-SMA, Desmin (DES), CD248, NG2, CD146 and
platelet derived growth factor receptor-beta (PDGFRB) genes (Chen et al.,
[34]) was analyzed in cultured HBVPs and HUVECs growing on plastic. All
markers were highly expressed in HBVPs. At the same time, these genes
were expressed at much lower level in HUVECs with the exception of
CD146. Based on these data we conclude that HBVPs kept pericyte
phenotype even growing on plastic.
Additional file 2: List of differentially expressed genes in HBVPs
identified in the microarray experiment included in TLDA. Seventy
four selected genes from eribulin and paclitaxel pericyte signatures were
analyzed by qPCR. Expression of housekeeping genes ACTB and GAPDH
was used for normalization. In parenthesis are numbers of genes specific
to eribulin, paclitaxel or both treatments versus control or each other.
Additional file 3: List of genes with significantly changed
expression level in HUVECs and HBVPs after the treatment with
eribulin or paclitaxel. Genes with signal intensities >100, p-values < 0.05
Agoulnik et al. Vascular Cell 2014, 6:3 Page 10 of 11
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treatment was conducted in triplicates. FC = Fold Change.
Additional file 4: Western blot analysis of selected proteins in
HBVPs treated with eribulin or paclitaxel. HBVPs were treated with
eribulin or paclitaxel for 24 hours at 10 × IC50 concentrations as
determined in cell proliferation assay. 0.1% DMSO was used as vehicle
control. A. Expression levels of several proteins were analyzed by western
blot analysis using the antibodies against α1A-tubulin (clone DM1A,
Millipore, Billerica, MA), β-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA), IGFBP3 (Santa Cruz Biotechnology) and β-actin (clone AC-15, Sigma
Aldrich St. Louis, MO). B. The signals of protein bands were quantified
using Multi Gauge version 3.0 software (Fuji Film, Tokyo, Japan). The
quantitative data of α1A-tubulin, β-tubulin and insulin-like growth factor
binding protein 3 were adjusted by the intensity of β-actin. The
calculated values and the intensity of β-actin are also shown.
Additional file 5: Effect of eribulin and paclitaxel on angiogenesis
in the sandwich tube formation assay. An aliquot (0.4 mL) of the
collagen gel mixture (Nitta Gelatin, Osaka, Japan) was added to each well
of 24-well plates and allowed to gel at 37°C. HUVECs were harvested by
trypsinization, counted and plated onto the gel at 1.5 × 105 cells per
well with human endothelial serum free medium (Life Technologies)
containing 10 ng/mL of EGF and 20 ng/mL VEGF (assay medium). After
overnight incubation at 37°C in a humidified atmosphere containing
5% CO2, medium was removed and 0.4 mL of collagen gel was added
to the cells and incubated for 4 hr at 37°C. An aliquot (1.5 mL) of
assay medium, containing 0.1% DMSO (as vehicle) or test compounds
were added to each well. HUVECs sandwiched in collagen gel were
incubated at 37°C in a humidified atmosphere containing 5% CO2 for
4 days and photomicrographs of capillaries were taken with a light
microscope using BZ-9000 (Keyence, Osaka, Japan) after adding 0.4 mL
of MTT solution. A. Tube length of each capillary was measured using
Angiogenesis Image Analyzer software version 2.0 (Kurabo). Assays
were performed in duplicate. Both compounds showed close IC50 values:
0.65 - 0.72 for eribulin and 1.18 - 1.26 for paclitaxel. B. Representative images
are shown.
Additional file 6: OD450 values (cell viability) of HBVP mono-culture
and HUVEC/HBVP co-culture. In the HBVP mono-culture, HBVPs were
diluted to densities of 1.87 × 105 cells/mL. In the HUVEC/HBVP co-culture,
HBVPs and AcGFP-expressing HUVECs were diluted and mixed to
densities of 1.87 × 105 cells/mL and 1.3 × 104 cells/mL with medium,
respectively. Cell suspensions were dispensed at 100 μL per well in
96-well plates and incubated for 15 days with culture medium changes
every 2 days. A. Cell viabilities were measured by the WST-8 assay.
HUVEC/HBVP co-culture showed slightly higher values compared to HBVP
mono-culture, because of HUVEC viability. Data represent means + SEM
from three independent experiments. B. Representative images are
shown.
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